A limited exploration of alternate clinically relevant components in the priming regimen suggested that the anti-PD-1 in AIP can be replaced with anti-CTLA-4, whereas switching “A” or “I” with anti-CTLA-4 elicited decreased therapeutic efficacy depending on the tumor model (Figures S2C–S2F). The gene discussed is CTLA4; the disease is autoimmune pancreatitis.